| 영문 | receptor | 한글 | 수용체 |
|---|---|---|---|
| 설명 | 세포질내 또는 세포표면에 존재하는 분자구조로서 특이물질과 선택적으로 결합하며 결합에 의해 특이한 생리적 작용을 나타낸다. 펩티드호르몬, 신경전달물질, 항원, 보체, 면역글로불린에 대한 세포표면 수용체와 스테로이드에 대한 세포질내 수용체가 있다. |
||
| 영문 | interferon | 한글 | 인터페론 |
|---|---|---|---|
| 설명 | 바이러스에 감염된 동물의 세포에서 생산되는 항바이러스성 단백질. 바이러스에 감염된 조직이 생산하는 항바이러스 작용이나 항종양작용 등 생리활성이 있는 당단백질을 말한다. 1957년 영국 국립의학연구소의 A.아이작스와 J.린든먼에 의해 알려졌다. 이들은 열처리한 바이러스를 달걀 내막의 세포에 처리하고 하루 동안 배양한 다음, 배양액을 추출하여 새로운 달걀 내막과 섞은 후, 살아 있는 바이러스를 집어넣은 결과, 바이러스의 분열이 억제되었고, 그 배양액을 넣지 않은 경우에는 바이러스가 분열되어 번식하였다. 이 실험의 의미는 바이러스가 동물세포에 침입하면 방어의 기능으로 그 동물세포는 인터페론을 생산하여 바이러스의 분열을 막는다는 것이다. 제일 많이 연구된 분야는 인간의 인터페론이다. 인터페론은 바이러스감염 및 내독소 투여, 나아가서는 항원자극 등에 반응하여 갖가지 세포로부터 방출된다. IFN이라고 약기. 현재, 3종(IFN-α, IFN-β, IFN-γ)이 알려져 있으며 각각 의약품으로 사용되고 있다. |
||
| ER | efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re... |
|---|---|
| RAR | rapidly adapting receptor; rat insulin receptor; retinoic acid receptor; right arm reclining; right ... |
| IFN | InterFeroN |
| INF-γ | Interferon-γ |
| FIF | feedback inhibition factor; fibroblast interferon; forced inspiratory flow; formaldehyde-induced flu... |
| IFN R | interferon receptor |
|---|---|
| IFN | 1-interferon |
| IF | 2-interferon |
| IFN alpha | Alpha interferon |
| alpha IFN | Alpha interferon |
| alpha interferon | <cytokine> Interferon which is released by leukocytes in response to a viral infection. A protein cytokine that is used as an anticancer agent. (15 Nov 1997) |
|---|---|
| antigen interferon | <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation. This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity. Synonym: antigen interferon, immune interferon. Pharmacological action: antineoplastic agent, antiviral agents. (20 Sep 2002) |
| beta interferon | A protein liberated by fibroblasts in response to a viral infection. (27 Sep 1997) |
| receptors, interferon | Specific molecular sites or structures on or in cells with which interferons react or to which they bind in order to modify the function of the cells. Interferons exert their pleiotropic effects through two different receptors. Alpha- and beta-interferon crossreact with common receptors, while gamma-interferon initiates its biological effects through its own specific receptor system. (12 Dec 1998) |
| immune interferon | <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation. This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity. Synonym: antigen interferon, immune interferon. Pharmacological action: antineoplastic agent, antiviral agents. (20 Sep 2002) |
| interferon | <cytokine> A family of glycoproteins derived from human cells which normally has a role in fighting viral infections by preventing virus multiplication in cells. They are secreted by vertebrate cells in response to a wide variety of inducers and confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions. Interferon-alpha is made by leucocytes and interferon-gamma by fibroblasts after viral infection. Interferon-alpha and -beta are also called type I interferons, interferon-gamma as Type II interferons, more usually classed as cytokines. Pharmacological action: antineoplastic agent, antiviral agents. (20 Sep 2002) |
| interferon-alpha | <cytokine> One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells when exposed to live or inactivated virus, double-stranded RNA, or bacterial products. It is the major interferon produced by virus-induced leukocyte cultures and, in addition to its pronounced antiviral activity, causes activation of NK cells. It is used experimentally in the treatment of hairy-cell leukaemia. A number of different subtypes exist that are elaborated by leukocytes in response to viral infection or stimulation with double-stranded RNA; IFN-alpha-2A and -2B are protein products made by recombinant DNA techniques and are used as antineoplastic agents. See: interferon-alpha 2a, interferon-alpha 2b Synonym: leukocyte interferon. Pharmacological action: antineoplastic agent, antiviral agent. (20 Sep 2002) |
| interferon-alpha 2a | <cytokine> Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. Pharmacological action: antineoplastic agent, antiviral agents. Chemical name: Interferon-alphaA (human leukocyte protein moiety reduced) (12 Dec 1998) |
| interferon-alpha 2b | <chemical> Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. Pharmacological action: antineoplastic agent, antiviral agents. (12 Dec 1998) |
| interferon-b2 | <cytokine> A cytokine that stimulates the growth and differentiation of human B-cells and is also a growth factor for hybridomas and plasmacytomas. It is produced by many different cells including T-cells, monocytes, and fibroblasts. A single chain 25 kD cytokine originally described as a pre B-cell growth factor, now known to have effects on a number of other cells including T-cells which are also stimulated to proliferate. An inducer of acute phase proteins and a colony-stimulating factor acting on mouse bone marrow. Acronym: IL-6 (12 Dec 1998) |
| interferon-beta | <cytokine> One of the type I interferons produced by fibroblasts in response to stimulation by live or inactivated virus or by double-stranded RNA. It is a cytokine with antiviral, antiproliferative, and immunomodulating activity. Synonym: fibroblast interferon. Pharmacological action: adjuvants, immunologic, antineoplastic agent, antiviral agents. Chemical name: Interferon-alphaB (human leukocyte protein moiety reduced) (12 Dec 1998) |
| interferon-gamma | <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation. This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity. Synonym: antigen interferon, immune interferon. Pharmacological action: antineoplastic agent, antiviral agents. (20 Sep 2002) |
| interferon inducers | Agents that promote the production and release of interferons. They include mitogens, lipopolysaccharides, and the synthetic polymers poly a-u and poly I-c. Viruses, bacteria, and protozoa have been also known to induce interferons. (12 Dec 1998) |
| interferon type I | <chemical> Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (interferon-alpha and interferon-beta). Pharmacological action: antineoplastic agent, antiviral agents. (12 Dec 1998) |
| interferon type II | <chemical> The major interferon produced by mitogenically or antigenically stimulated lymphocytes. It is structurally different from type I interferon (interferon type I) and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease. Pharmacological action: antineoplastic agent, antiviral agents. Chemical name: Interferon-gamma (human lymphocyte protein moiety reduced) (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|